Outlook Therapeutics, Inc.
OTLKHealthcare|Biotechnology|US
$0.44
-0.00 (-0.61%)
DCF Value
$0.95
Cash / Share
$0.08
Clinical Trials (5)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05112861 A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders | Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration | P3 | Active | 120 | Open-label | bevacizumab |
| NCT03834753 A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | P3 | Completed | 228 | RCT, Double-blind | bevacizumab, ranibizumab |
| NCT06190093 A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration | P3 | Completed | 400 | Double-blind | bevacizumab, ranibizumab |
| NCT03844074 A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | P3 | Completed | 61 | RCT, Double-blind | bevacizumab, ranibizumab |
| NCT04516278 A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders | Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration | P3 | Completed | 197 | Open-label | bevacizumab |